Brief: United Laboratories International Updates On Amoxicillin Sodium And Clavulanate Potassium
17/07/2025 16:17
July 17 (Reuters) - United Laboratories International Holdings Ltd 3933.HK: AMOXICILLIN SODIUM AND CLAVULANATE POTASSIUM FOR INJECTION APPROVED BY CHINA NMPA AMOXICILLIN SODIUM AND CLAVULANATE POTASSIUM FOR INJECTION PASSED CONSISTENCY EVALUATION Further company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million